BioRestorative Therapies

04/24/2026

Check out the latest milestones from in a letter to shareholders from CEO, Lance Alstodt.

- Completed Phase 2 enrollment for BRTX-100
- Achieved positive Type B meeting; aligned on BLA pathway
- Initiation of Phase 3 enabling activities
- Strengthened capital position with $5 million public offering
- Advanced commercial BioCosmeceutical strategy
- Continued progress on ThermoStem® metabolic platform

Read the full letter: bit.ly/46D9x8m

U.S. Food and Drug Administration

04/22/2026

announces a strategic partnership with David J. Goldberg, MD, JD, internationally recognized as one of the foremost innovators in laser , regenerative aesthetics, and clinical research leadership.

This collaboration establishes an independent clinical validation pathway, expands access to influential physician networks, and strengthens the foundation for possible broad commercial growth across professional, biologic dermal, and consumer channels.

Read the full press release here: bit.ly/4mJ2YYF

04/17/2026

CEO Lance Alstodt walks Ira S. Pastor through ' unique approach to on the Progress, Potential, And Possibilities Podcast.

Listen to their full discussion: bit.ly/41qEoCc

04/15/2026

The team is working hard to advance stem cell–based therapies and innovative biologic technologies designed to address significant unmet needs in musculoskeletal and metabolic disorders.

CEO Lance Alstodt recently shared insights on the progress of ’s lead candidate, BRTX-100, the evolving regulatory and manufacturing landscape for autologous therapies, and the broader potential for regenerative platforms to reshape treatment approaches for chronic conditions with @‌Drug Development & Delivery.

Read the full Q&A here:

Lance Alstodt, CEO of BioRestorative Therapies, discusses the development of its lead cell therapy candidate BRTX-100, the evolving regulatory and manufacturing landscape for autologous therapies, and how regenerative platforms could reshape treatment paradigms for chronic conditions.

04/10/2026

CEO, Lance Alstodt, discusses our mission to build the future of on the Progress, Potential, And Possibilities podcast.

Listen to the full episode here: https://bit.ly/41qEoCc

Imagine treating back pain not with surgery, not with opioids—but by using your own stem cells to repair the damage at its source.Lance Alstodt is President,...

04/08/2026

Today is !

As a leading manufacturer of -based formulations, is redefining stem cell therapy and skin health through the power of regenerative science.

Our are produced without animal derived ingredients or antibiotics, supporting optimal biocompatibility. Similar to top athletes training at altitude, our team’s hypoxic culturing approach enhances cell survival after application and increases overall adaptability.

Learn more: https://biorestorative.com/biocosmeceuticals/

04/07/2026

Today, announced a strategic collaboration with 203 Creates, LLC, a Stamford, Connecticut-based firm specializing in the development, marketing, and growth of luxury, premium, and science-backed brands.

The collaboration is designed to advance BioRestorative’s platform by establishing a differentiated brand architecture and executing a comprehensive commercialization strategy.

Read the full release here: https://bit.ly/4bWSC3Q

04/02/2026

We have developed a new class of high-performance cosmetic and dermatological products developed in a cGMP ISO-7 certified facility. Our BioCosmeceuticals line blends cutting-edge biologic innovation with clinical-grade quality to redefine aesthetic care.

Learn more here: bit.ly/4sN69Rj

U.S. Food and Drug Administration

03/30/2026

announced blinded data from its Phase 2 evaluating hypoxic-cultured mesenchymal for the treatment of chronic lumbar disc disease at the 2026 Orthopaedic Research Society Annual Meeting this weekend.

The data showed 50% or more of patients reporting >50% improvement in key pain and function scales with no adverse events related to dose-limiting toxicities associated with hypoxic-cultured mesenchymal stem cells.

Full press release here: bit.ly/4sGF3LP

03/27/2026

.

announces new, blinded data on ~45 patients from its Phase 2 evaluating hypoxic-cultured mesenchymal for the treatment of chronic lumbar disc disease.

These data have been accepted for presentation at the 2026 Orthopaedic Research Society Annual Meeting, which will be held March 27-31, 2026, at the Charlotte Convention Center in Charlotte, North Carolina.

Full press release here: https://ir.biorestorative.com/news-events/press-releases/detail/238/biorestorative-therapies-to-present-positive-phase-2-blinded-data-for-brtx-100-demonstrating-meaningful-improvements-in-pain-and-function-in-chronic-lumbar-disc-disease

03/26/2026

CEO Lance Alstodt joined Will Tjernlund on the to discuss our innovative stem cell therapies targeting chronic pain and metabolic disorders.

The discussion explores our therapeutic products, clinical trials, market potential, and future plans, providing insights into regenerative medicine and biotech investment strategies.

Tune in today!

Spotify: https://open.spotify.com/episode/1pYPO0YkymhXaxpTIv6HMM

Apple Podcasts: https://podcasts.apple.com/us/podcast/biorestorative-therapies-%24brtx-ep-059-nano-cap-podcast/id1725050280?i=1000756829667

03/24/2026

Over 25 million Americans live with chronic lower back pain each year and traditional treatments aren’t cutting it.

BRTX-100 is exploring a different approach: a single-injection therapy using a patient’s own stem cells to target and help repair damaged spinal discs.

Learn more about our Phase 2 progress: biorestorative.com/brtx-100-2